Cellectis S.A. CLLS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -77.69%
- 1 year
- -68.97%
- Open
- 1.15
- Prev close
- 1.17
- Mkt cap
- 108.79M
- Vol
- 12.27K
- Avg vol
- 106.06K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.15
- Forward P/E
- -2.07
- Beta
- 3.20
- Short ratio
- 1.41
- Inst. own
- 16.65%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.88
- 200-d avg
- 2.26
- 1y target
- 6.67
5D chart
Signals (41)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 10:55 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:25 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:50 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:05 PM | 6 days ago |
News
6 days ago globenewswire.com
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of…
6 days ago globenewswire.com
Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026
Un taux d'édition in vivo du gène APOC3 humain atteignant 70% après une seule administration Une réduction de 76 % du taux de triglycérides après une dose unique dans un modèle murin de la maladie…
1 week ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
1 week ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
2 weeks ago globenewswire.com
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. (“Cellectis”…
2 weeks ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
2 weeks ago globenewswire.com
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
2 weeks ago globenewswire.com
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors…
2 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
3 weeks ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
3 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
3 weeks ago globenewswire.com
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
1 month ago marketbeat.com
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS).
1 month ago defenseworld.net
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46
Cellectis S.A. (NASDAQ: CLLS - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment…
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A.
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS). Such investors are advised to…
1 month ago gurufocus.com
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
1 month ago businesswire.com
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CLLS--CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law.
1 month ago benzinga.com
This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded NU, BAK, CLLS and CBZ; price targets for NU, BAK and CLLS were cut sharply.
1 month ago benzinga.com
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
-
1 month ago benzinga.com
Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
1 month ago benzinga.com
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
-
1 month ago benzinga.com
Wells Fargo Maintains Equal-Weight on Cellectis, Lowers Price Target to $3
Wells Fargo analyst Yanan Zhu maintains Cellectis (NASDAQ:CLLS) with a Equal-Weight and lowers the price target from $4 to $3.
-
1 month ago benzinga.com
Baird Maintains Outperform on Cellectis, Lowers Price Target to $8
Baird analyst Jack Allen maintains Cellectis (NASDAQ:CLLS) with a Outperform and lowers the price target from $10 to $8.
1 month ago benzinga.com
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Veea shares surged 58% premarket on a NovaGen merger plan and $10M GeoNova investment, while other stocks posted notable gains and losses.
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
1 month ago benzinga.com
Crude Oil Jumps 3%; Corning Shares Move Lower
U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while gold, silver and copper declined.
1 month ago benzinga.com
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
U.S. stocks fell Monday, led by a 2% tech decline. Nvidia may invest $10B in Anthropic; oil jumped 4.2%, while European markets mostly slipped.
1 month ago benzinga.com
Cellectis Pivots to Gene Editing in Major Overhaul
Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
1 month ago benzinga.com
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.
1 month ago benzinga.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
-
1 month ago benzinga.com
Cellectis Exits Lasme-Cel And Eti-Cel Development To Focus On In Vivo Gene Editing Pipeline, Targeting Cash Runway Extension Into H2 2028
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by…
-
2 months ago benzinga.com
Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
4 months ago benzinga.com
Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the…
-
5 months ago benzinga.com
Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9
Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.
-
5 months ago benzinga.com
Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming…
-
5 months ago benzinga.com
Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.27) by 40.74 percent. This is a 5.88 percent increase over losses of $(0.17)…
-
6 months ago benzinga.com
Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research…
-
6 months ago benzinga.com
Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target
Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.
6 months ago benzinga.com
Allogene Therapeutics Stock Hits 52-Week High - Here's Why
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
6 months ago benzinga.com
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
7 months ago benzinga.com
Earnings Scheduled For March 19, 2026
Earnings Scheduled For March 19, 2026
10 months ago benzinga.com
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday